Tag Archives: NYSE:PFE

Cantor Fitzgerald Believes Pfizer (NYSE: PFE) Still Has Room to Grow

In a report released yesterday, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Pfizer (NYSE: PFE), with a price target of $45. The company’s shares closed yesterday at $42.85, close to its 52-week high of $42.92. Chen said:

Credit Suisse Maintains Their Hold Rating on Pfizer (PFE)

In a report released today, Vamil Divan from Credit Suisse maintained a Hold rating on Pfizer (NYSE: PFE), with a price target of $40. The company’s shares opened today at $41.78, close to its 52-week high of $42.77. According to

Pfizer (PFE) Gets a Hold Rating from Goldman Sachs

In a report released today, Jami Rubin from Goldman Sachs maintained a Hold rating on Pfizer (NYSE: PFE), with a price target of $45. The company’s shares opened today at $41.50, close to its 52-week high of $42.77. According to

Barclays Reaffirms Their Hold Rating on Pfizer (PFE)

In a report released today, Geoff Meacham from Barclays maintained a Hold rating on Pfizer (NYSE: PFE), with a price target of $40. The company’s shares opened today at $41.58, close to its 52-week high of $42.77. According to TipRanks.com,

BMO Capital Believes Pfizer (NYSE: PFE) Still Has Room to Grow

BMO Capital analyst Alex Arfaei maintained a Buy rating on Pfizer (NYSE: PFE) today and set a price target of $44. The company’s shares opened today at $42.52, close to its 52-week high of $42.77. According to TipRanks.com, Arfaei is

Pfizer Gets a Hold Rating from Goldman Sachs

In a report released today, Jami Rubin from Goldman Sachs maintained a Hold rating on Pfizer (NYSE: PFE), with a price target of $42. The company’s shares opened today at $40.27, close to its 52-week high of $40.32. According to